Search

The article discusses the findings from a large observational study of a U.S. sample of adults with normal thyroid function, led by Dr. Ralph I. Lawton, which suggested that subclinical variation in the hypothalamic-pituitary-thyroid (HPT) axis effector hormone triiodothyronine (T3) is an important and overlooked factor linking socioeconomic forces, human biology, and aging. Topics include comments from thyroidology expert Antonio Bianco and large variations in T3.

A retrospective study of US women under the age of 65 found that having a first menstrual period at age 10 or younger was associated with a higher risk of type 2 diabetes and stroke in women with diabetes. The study analyzed data from 17,377 women who participated in a National Health and Nutrition Examination Survey from 1999 to 2018. Women who had their first period at age 10 or younger had a significantly greater risk of type 2 diabetes, and among women with diabetes, they had a significantly greater risk of stroke. The study suggests that early age at menarche may be an early indicator of cardiometabolic disease in women. However, the study has limitations, such as potential selection bias and recall bias. The researchers recommend further examination and prevention strategies for women with early-life exposures like early age at menarche. [Extracted from the article]

A retrospective study of US women under the age of 65 found that having a first menstrual period at age 10 or younger was associated with a higher risk of type 2 diabetes and stroke in women with diabetes. The study analyzed data from 17,377 women who participated in a National Health and Nutrition Examination Survey from 1999 to 2018. Women who had their first period at age 10 or younger had a significantly greater risk of type 2 diabetes, and among women with diabetes, they had a significantly greater risk of stroke. The study suggests that early age at menarche may be an early indicator of cardiometabolic disease in women. However, the study has limitations, including potential selection bias and recall bias. The researchers recommend further examination and prevention strategies for women with early-life exposures such as early age at menarche. [Extracted from the article]

The article discusses a retrospective study linking an early age at first menstrual period (menarche) of 10 or younger with an increased risk of type 2 diabetes and stroke in women under 65 with diabetes. Topics include the methodology involving data analysis of 17,377 women from 1999 to 2018, the association between early menarche and diabetes/stroke risk, and the practical implications for diabetes prevention strategies in women with early-life exposures.

A new study suggests that self-monitoring blood pressure during the early postpartum period can lead to better blood pressure control and prevent cardiovascular events in women with hypertensive pregnancies. The study, which included 220 women with preeclampsia or gestational hypertension, found that those who monitored their blood pressure daily and received guidance from clinicians had lower average diastolic blood pressure at 9 months compared to those receiving usual care. The study also found that short-term postnatal optimization of blood pressure control was associated with better cardiac remodeling changes. The findings suggest a need for a paradigm shift in postpartum care for women affected by hypertensive pregnancies. [Extracted from the article]

A recent study conducted in Nigeria found that using a "smart" digital stethoscope with artificial intelligence (AI) technology doubled the detection of peripartum cardiomyopathy in obstetric patients. Peripartum cardiomyopathy is a life-threatening condition that is difficult to diagnose due to overlapping symptoms with pregnancy. The digital stethoscope provided accurate readings and identified 92% of women with reduced ejection fraction. The study suggests that this AI tool could be valuable in areas with a high prevalence of peripartum cardiomyopathy, but further research is needed to determine its effectiveness compared to other screening methods. [Extracted from the article]

The article discusses newer antiobesity medications, such as semaglutide and tirzepatide, which appear to lower the body's defended fat mass but do not permanently fix it at a lower point. It suggests that patients with obesity might need to take these medications indefinitely until cellular and molecular mechanisms regulating body fat mass in obesity are identified and repaired; and highlighting intermittent therapy to address challenges like high costs and limited drug availability.

The article focuses on the emergence of highly effective antiobesity medications, exploring nutrient-stimulated hormone therapies and upcoming activin-receptor inhibitors. Topics include an overview of late-phase development therapies, such as GLP-1 receptor agonists, GIP agonists, glucagon and amylin; emphasizing their varied responses in promoting substantial weight reduction; and discusses promising drugs like tirzepatide, survodutide, and orforglipron.

The article present a research suggesting that self-monitoring blood pressure during the early postpartum period in women with hypertensive pregnancies could lead to better blood pressure control and potentially prevent cardiovascular events. It discusses a randomized trial of 220 women with preeclampsia or gestational hypertension; and showing that those who self-monitored blood pressure and clinician-guided advice.

The article focuses on the limited long-term benefits of prolonged "water fasting" and Buchinger fasting, highlighting very low-calorie diets. Topics include the initial weight loss in health markers observed during fasting, the need for caution and medical supervision, and the challenges of maintaining the benefits over time.

The article explains the association between a high intake of ultraprocessed food & beverages (UPF) and increased mortality risk in older adults with type 2 diabetes, even when adhering to a healthy Mediterranean diet. It highlights the need to limit UPF consumption; information on food processing in nutrition labels; and UPF, characterized by minimal whole foods and high levels of unhealthy ingredients, may exacerbate health risks in individuals with type 2 diabetes.

The article present a 12-year observational study of United Kingdom (UK) Biobank data, which found that individuals with prediabetes, undiagnosed diabetes & diagnosed diabetes had a higher risk of cardiovascular disease (CVD), while those with low-normal blood glucose levels had a lower risk of CVD. It emphasizes the importance of addressing modifiable factors such as weight reduction, antihypertensive & statin medications to reduce CVD risk across the glycemic spectrum, especially among women.

The article suggests genetic factors play a significant role in weight regain, with people genetically predisposed to abdominal obesity regaining more weight around their waist after weight loss. It highlights the distinction between genetic effects on abdominal obesity and general obesity during weight regain; providing new insights into the mechanisms of weight regain; and the potential for tailored treatments based on genetic predisposition.

The article focuses on the results of a study comparing an automated insulin delivery (AID) system (CamAPS FX) with standard insulin delivery in pregnant women with type 1 diabetes. It mentions that the study found that the AID system significantly improved glucose control, increasing the time spent in the target blood glucose range during pregnancy. Researchers recommend offering this system to pregnant women with type 1 diabetes, as it provides better maternal glucose control.

The article focuses on dosing trial of survivodutide, a dual glucagon-like peptide–1 (GLP-1) and glucagon receptor agonist, for individuals with overweight/obesity but without type 2 diabetes. It discusses trial demonstrated significant and striking weight loss effects with survivodutide; leading to the consideration of its potential as a treatment for obesity and nonalcoholic fatty liver disease (NAFLD); and further research is needed to assess its long-term effectiveness.

The article discusses the low rate of bariatric surgery for patients with a body mass index (BMI) of 30-35 (class 1 obesity), recommendations from medical societies to expand the indication. It discusses data from a U.S. national registry reveals that metabolic and bariatric surgeries were performed in this weight category, with most surgeries being conducted in patients with a BMI greater than 35; and the need to increase awareness and access to bariatric surgery for class 1 obesity patients.

The article discusses the potential disease-modifying effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), like liraglutide and semaglutide, on knee osteoarthritis (KOA). Topics including a randomized controlled trial, an observational study, and a preclinical trial, investigated the potential benefits of GLP-1 RAs for KOA; results in terms of weight loss and potential disease modification; and the effects of GLP-1 RAs on KOA progression and symptom relief.

The article discusses about phase 3 clinical trials, OASIS and PIONEER PLUS, which support the use of higher doses of oral semaglutide beyond the currently approved dose for type 2 diabetes. It discusses the trials showed that higher doses of oral semaglutide were effective in reducing body weight and improving glycemic control in patients with prediabetes, diabetes and obesity; and offering potential additional treatment options for these patient populations.

The article discusses a study that suggests a low-carbohydrate breakfast, can help decrease glycemic variability throughout the day in individuals with type 2 diabetes. It discusses that the research found that a low-carb, high-fat breakfast centered around eggs can limit hyperglycemic swings; improve blood glucose control in people with type 2 diabetes; and offering a simple and effective approach to managing postprandial hyperglycemia and lowering glycemic variability in this population.

The article offers information on the potential benefits of glucagonlike peptide–1 (GLP-1) receptor agonists, such as semaglutide, in curbing addictions and compulsive behaviors. Anecdotal reports suggest that patients taking these drugs for type 2 diabetes or weight loss also lost interest in addictive and compulsive behaviors.

The article presents findings from a phase 2 trial on the combination drug CagriSema, which consists of the long-acting amylin analog cagrilintide and the glucagon-like peptide-1 (GLP-1) agonist semaglutide. The trial demonstrated that CagriSema led to significant weight loss and improved glucose control in patients with type 2 diabetes compared to using either drug alone.

The article discusses research by Caroline Amelie Koch and colleagues, reported in the European Heart Journal on May 24, 2023. It mentions that the meta-analysis of several trials indicates that individuals following vegan or plant-based diets have lower levels of LDL cholesterol, total cholesterol, and apolipoprotein B compared to those following an omnivore diet, suggesting that plant-based diets have the potential to reduce the risk of cardiovascular disease.

The article focuses on a meta-analysis of 30 trials, indicating that individuals who followed a vegan or vegetarian diet. It discusses that vegan or vegetarian had lower levels of LDL cholesterol, total cholesterol and apolipoprotein B compared to those who followed an omnivore diet. The study suggests that plant-based diets have the potential to reduce the risk of cardiovascular disease and contribute to a more sustainable future by reducing greenhouse gas emissions.

The article focuses on lifestyle medicine practitioners describing the safe and effective deprescribing of glucose-lowering medications after patients make lifestyle changes. Topics include the use of a whole-food; predominantly plant-based eating plan; physical activity and other lifestyle changes to reduce the need for pharmacotherapy; as well as the protocols followed by practitioners for deprescribing specific medications based on their potential harms and benefits.

The article focuses on whether Ozempic, Wegovy or Mounjaro, three medications used for weight loss, can cause hair loss. It discusses that dermatologists and endocrinologists agree that hair loss is rare and more likely to be associated with rapid weight loss rather than the medications themselves; and also suggesting that the benefits of treating obesity should be weighed against the low risk of temporary hair loss.

The article focuses on the potential role of vitamin D supplementation in long COVID-19. It highlights that patients with long COVID-19 had lower levels of vitamin D, particularly those with brain fog, suggesting that vitamin D deficiency may be linked to long COVID-19; evaluating vitamin D levels in COVID-19 patients after hospital discharge; and conducting randomized controlled trials to test the effectiveness of vitamin D supplementation as a preventive strategy for COVID-19 sequelae.

The article focuses on the use of continuous glucose monitors (CGMs) to complement hemoglobin A1c (A1c) readings in patients with type 2 diabetes. It discusses that the study found that time-in-range (TIR) readings from CGMs provide additional information about glucose control and can help healthcare professionals make better treatment decisions; and leading to improved glycemic control and a reduction in diabetes-related complications.

The article focuses on the impact of COVID-19 on infants exposed in the womb. Topics include lower birth weight of the infants but experience greater weight gain in their first year of life, potentially indicating a catch-up response to prenatal growth deficit; this accelerated growth raises concerns about the development of obesity, diabetes or cardiovascular disease in the future; and need for further research with larger sample sizes and longer follow-up.

the article presents a study which reveals that infants who were exposed to Covid-19 had a lower weight and body mass index at birth, but greater weight gain, during the first year of life. It informs that researchers Andrea G. Edlow and Lindsay T. Fourman stated that the study raise concern about whether children born to mothers with prenatal COVID-19 go on to develop obesity, diabetes, or cardiovascular disease.

The article focuses on the recommendation to use age rather than weight as a screening criterion for diabetes, particularly among individuals aged 35-70. The topics discussed include the higher risk of diabetes in certain ethnic groups at lower cutoffs; the comparison of different screening scenarios; and also discusses about the need to address structural barriers to achieve equity in diagnosis and treatment.

The article focuses on the safety profile of Sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with chronic kidney disease (CKD) and type 2 diabetes. It suggests that although there may be risks of lower limb amputations; nonvertebral fractures; and genital infections associated with SGLT2 inhibitors compared to GLP-1 agonists; and also menytions about the cardiovascular and renoprotective benefits outweigh these risks.

The article focuses on the overpricing of obesity drugs and the need for changes to address the issue. The topics discussed include the significant price difference between branded obesity medications and estimated minimum prices for potential generic versions, the call for improved access to affordable medications, and the importance of prioritizing the treatment of diabetes and clinical obesity at low prices to save lives.

The article focuses on the lack of kidney function preservation in seniors undergoing early parathyroidectomy for primary hyperparathyroidism (PHPT). Topics include the absence of reduced risk in kidney function decline for older adults; potential benefits of parathyroidectomy for younger patients in preventing chronic kidney disease; and the importance of considering other factors such as fractures, kidney stones and cardiovascular disease when deciding on surgery for older adults with PHPT.

The article offers information related to"Similar 10-year survival after CABG, PCI in heavy calcification" by Marlene Busko, which appeared in the periodical "Internal Medicine News" on January 7, 2022, s presented. Topic includes on the Patients with complex coronary artery disease either three-vessel disease and/or left main disease who also had heavy coronary artery calcification (CAC) had greater all-cause mortality 10 years after revascularization, compared with those without such lesions.